|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
|
US7232818B2
(en)
*
|
2004-04-15 |
2007-06-19 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
|
US8129346B2
(en)
|
2004-04-15 |
2012-03-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
EP2030981B1
(en)
|
2004-05-10 |
2014-07-09 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
AU2005243140A1
(en)
*
|
2004-05-10 |
2005-11-24 |
Proteolix, Inc. |
Synthesis of amino acid keto-epoxides
|
|
SG157365A1
(en)
|
2004-12-03 |
2009-12-29 |
Dana Farber Cancer Inst Inc |
Compositions and methods for treating neoplastic diseases
|
|
PT2260835E
(pt)
|
2004-12-07 |
2013-05-28 |
Onyx Therapeutics Inc |
Composição para inibição do proteassoma
|
|
MY171061A
(en)
|
2005-11-09 |
2019-09-24 |
Onyx Therapeutics Inc |
Compounds for enzyme inhibition
|
|
CA2657213C
(en)
|
2006-06-19 |
2017-01-03 |
Proteolix, Inc. |
Peptide epoxyketones for proteasome inhibition
|
|
US20090234150A1
(en)
*
|
2006-07-14 |
2009-09-17 |
Peter Carmeliet |
Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
|
|
US7642369B2
(en)
*
|
2006-09-12 |
2010-01-05 |
University Of Kentucky Research Foundation |
Epoxyketone-based immunoproteasome inhibitors
|
|
AU2013203566B2
(en)
*
|
2007-10-04 |
2016-10-13 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
KR20170125413A
(ko)
|
2007-10-04 |
2017-11-14 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
|
AU2016231532B2
(en)
*
|
2007-10-04 |
2018-05-10 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
|
EP2088205A1
(en)
|
2008-02-11 |
2009-08-12 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
|
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
|
CN102089312A
(zh)
|
2008-05-12 |
2011-06-08 |
尼瑞斯药品公司 |
作为蛋白酶体抑制剂的Salinosporamide衍生物
|
|
EP3090737A1
(en)
|
2008-10-21 |
2016-11-09 |
Onyx Therapeutics, Inc. |
Combination therapy with peptide epoxyketones
|
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
|
US20110009332A1
(en)
*
|
2009-07-09 |
2011-01-13 |
Southwest Research Institute |
Therapeutic Treatment Of Wounds
|
|
GB0914883D0
(en)
|
2009-08-26 |
2009-09-30 |
Univ Belfast |
Compound
|
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
|
EP2542238B1
(en)
|
2010-03-01 |
2015-08-12 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
NZ602872A
(en)
|
2010-04-07 |
2014-05-30 |
Onyx Therapeutics Inc |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
|
US9272014B2
(en)
|
2011-03-29 |
2016-03-01 |
Texas Tech University System |
Galectin-3C combination therapy for human cancer
|
|
WO2013009923A1
(en)
*
|
2011-07-13 |
2013-01-17 |
Creighton University |
Methods of promoting neuron growth
|
|
CN104039328B
(zh)
|
2011-11-11 |
2018-10-09 |
米伦纽姆医药公司 |
对蛋白酶体抑制剂的反应的生物标记
|
|
CN104126017A
(zh)
|
2011-11-11 |
2014-10-29 |
米伦纽姆医药公司 |
对蛋白酶体抑制剂的反应的生物标记
|
|
CA2862492A1
(en)
|
2012-01-24 |
2013-08-01 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
|
WO2013123254A1
(en)
|
2012-02-15 |
2013-08-22 |
Cydex Pharmaceuticals, Inc. |
Manufacturing process for cyclodextrin derivatives
|
|
SG11201407337QA
(en)
|
2012-05-08 |
2014-12-30 |
Onyx Therapeutics Inc |
Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
|
|
US20140105921A1
(en)
|
2012-07-09 |
2014-04-17 |
Onyx Therapeutics, Inc. |
Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
|
|
EP2874605A1
(en)
|
2012-07-18 |
2015-05-27 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
|
US20150218212A1
(en)
*
|
2012-08-21 |
2015-08-06 |
Fluorinov Pharma Inc. |
Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
|
|
KR102112119B1
(ko)
|
2012-10-22 |
2020-05-19 |
사이덱스 파마슈티칼스, 인크. |
알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
|
|
SG10201913777XA
(en)
|
2013-03-13 |
2020-03-30 |
Sanofi Sa |
Compositions comprising anti-cd38 antibodies and carfilzomib
|
|
EA030957B1
(ru)
|
2013-03-14 |
2018-10-31 |
Оникс Терапьютикс, Инк. |
Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
|
|
AR095426A1
(es)
|
2013-03-14 |
2015-10-14 |
Onyx Therapeutics Inc |
Inhibidores tripeptídicos de la epoxicetona proteasa
|
|
MX372671B
(es)
|
2013-07-19 |
2020-04-23 |
Onyx Therapeutics Inc |
Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
|
|
CN103360348B
(zh)
*
|
2013-07-25 |
2015-06-24 |
苏州鹏旭医药科技有限公司 |
一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
|
|
CN105517998A
(zh)
*
|
2013-09-06 |
2016-04-20 |
桑多斯股份公司 |
通过曼尼希反应立体选择性合成二醇和三醇以及它们在卡非佐米合成中的用途
|
|
CN105518019A
(zh)
*
|
2013-09-06 |
2016-04-20 |
桑多斯股份公司 |
肽环氧基酮的合成
|
|
WO2015121769A1
(en)
|
2014-02-13 |
2015-08-20 |
Ranbaxy Laboratories Limited |
Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
|
|
CN103864889B
(zh)
*
|
2014-04-04 |
2017-01-11 |
重庆泰濠制药有限公司 |
环氧酮化合物、其制备方法及卡非佐米的制备方法
|
|
PT3183295T
(pt)
|
2014-08-22 |
2023-11-03 |
Cydex Pharmaceuticals Inc |
Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
|
|
WO2016046843A1
(en)
|
2014-09-24 |
2016-03-31 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
|
|
US20160115198A1
(en)
|
2014-10-27 |
2016-04-28 |
Apicore Us Llc |
Methods of making carfilzomib and intermediates thereof
|
|
CN104402973A
(zh)
*
|
2014-11-24 |
2015-03-11 |
重庆泰濠制药有限公司 |
一种卡非佐米无定型晶的制备方法
|
|
CN107548400A
(zh)
|
2014-12-02 |
2018-01-05 |
费森尤斯卡比肿瘤学有限公司 |
卡非佐米的纯化方法
|
|
US10301353B2
(en)
|
2014-12-31 |
2019-05-28 |
Dr. Reddy's Laboratories Limited |
Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
|
|
US10544189B2
(en)
|
2015-04-22 |
2020-01-28 |
Msn Laboratories Private Limited |
Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
|
|
WO2016185450A1
(en)
*
|
2015-05-21 |
2016-11-24 |
Laurus Labs Private Limited |
An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
|
|
CN106317188A
(zh)
*
|
2015-06-18 |
2017-01-11 |
重庆医药工业研究院有限责任公司 |
一种制备卡非佐米无定型物的方法
|
|
WO2017032487A1
(en)
|
2015-08-27 |
2017-03-02 |
Technische Universität München |
Proteasome inhibitor comprising a signal-emitting moiety
|
|
EP3411363A1
(en)
|
2015-12-11 |
2018-12-12 |
Mylan Laboratories, Limited |
Crystalline and amorphous forms of carfilzomib
|
|
TWI636052B
(zh)
*
|
2015-12-31 |
2018-09-21 |
中化合成生技股份有限公司 |
無定形卡非佐米(i)的製備方法
|
|
US11306107B2
(en)
|
2016-02-25 |
2022-04-19 |
Amgen Inc. |
Compounds that inhibit MCL-1 protein
|
|
TWI759301B
(zh)
|
2016-05-24 |
2022-04-01 |
美商安美基公司 |
聚乙二醇化卡非佐米化合物
|
|
WO2018024645A1
(en)
|
2016-08-02 |
2018-02-08 |
Synthon B.V. |
Process for making carfilzomib
|
|
ES2842575T3
(es)
|
2016-08-05 |
2021-07-14 |
Amgen Inc |
Síntesis de (S)-2-amino-4-metil-1-((R)-2-metiloxiran-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma
|
|
ES2874683T3
(es)
|
2016-09-14 |
2021-11-05 |
Fresenius Kabi Oncology Ltd |
Un proceso para la purificación de un intermedio de carfilzomib
|
|
EP3512602B1
(en)
|
2016-09-16 |
2024-03-27 |
HSF Pharmaceuticals |
Inhibitors of heat shock factors (hsf) and uses thereof
|
|
EP3330260A1
(en)
|
2016-12-01 |
2018-06-06 |
Enantia, S.L. |
Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
|
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌の組合せ治療
|
|
AU2018370019C1
(en)
|
2017-11-16 |
2025-01-30 |
Amgen Inc. |
Stable compositions of pegylated carfilzomib compounds
|
|
WO2019113363A1
(en)
*
|
2017-12-08 |
2019-06-13 |
NeuroDiagnostics LLC |
Synchronized cell cycle gene expression test for alzheimer's disease and related therapeutic methods
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
US10689416B2
(en)
*
|
2017-12-30 |
2020-06-23 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
AU2018357829B2
(en)
*
|
2017-12-30 |
2019-09-26 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
MX2020013853A
(es)
*
|
2018-06-22 |
2021-05-27 |
Ucl Business Ltd |
Compuestos innovadores.
|
|
EP4041747A4
(en)
*
|
2019-10-11 |
2023-10-18 |
Mayo Foundation for Medical Education and Research |
PROTEASOME HIBITORS
|
|
CA3175499A1
(en)
*
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
WO2024069240A2
(en)
|
2022-09-29 |
2024-04-04 |
Takeda Pharmaceutical Company Limited |
Cd38-binding fusion protein combination therapy
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
CN116768972A
(zh)
*
|
2023-06-25 |
2023-09-19 |
重庆药友制药有限责任公司 |
一种卡非佐米中间体的制备方法
|
|
WO2025035020A2
(en)
|
2023-08-09 |
2025-02-13 |
Amgen Inc. |
Methods of using carfilzomib
|
|
EP4685151A1
(en)
|
2024-07-24 |
2026-01-28 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Proteasome inhibitor
|